Form 4: Charles River Laboratories Director Acquires Shares and Stock Options

Virginia M. Wilson, a Director at Charles River Laboratories International, Inc. (CRL), reported the acquisition of common stock and stock options valued at $134.98 per share, aligning her interests with shareholders.

Summary

• Virginia M. Wilson, a Director of Charles River Laboratories International, Inc. (CRL), acquired 946 shares of common stock in the form of unvested restricted stock units (RSUs) on May 21, 2025.
• These RSUs were acquired at a price of $134.98 per share.
• The RSUs are set to vest upon the earlier of May 21, 2026, or the business day prior to the Company's next annual meeting of shareholders.
• Following this transaction, Ms. Wilson beneficially owns 4,911 shares of common stock directly.
• Additionally, Ms. Wilson acquired 2,076 stock options (right to buy) on May 21, 2025, with an exercise price of $134.98 per share.
• These stock options become exercisable upon the earlier of May 21, 2026, or the business day prior to the Company's next annual meeting of shareholders, and expire on May 21, 2035.
• The transactions were made pursuant to a Rule 10b5-1(c) contract, instruction, or written plan for the purchase or sale of equity securities.

Sentiment

Score: 7

Explanation: The sentiment is positive as a director's acquisition of shares and options indicates confidence in the company and aligns their interests with shareholders, which is generally viewed favorably.

Positives

• The acquisition of additional shares and stock options by a director indicates continued confidence in the company's future performance and aligns management's interests with those of shareholders.
• The use of a Rule 10b5-1 plan demonstrates a pre-planned and transparent approach to insider transactions.

Future Outlook

The acquired restricted stock units and stock options are subject to future vesting and exercisability, contingent on either a specific date (May 21, 2026) or the company's next annual meeting of shareholders, indicating a long-term incentive structure.

Management Comments

• The transaction reflects Virginia M. Wilson's acquisition of equity compensation as a Director, aligning her financial interests with the long-term performance of Charles River Laboratories.

Industry Context

This Form 4 filing is a routine disclosure of insider trading activity, common across all publicly traded companies, reflecting compensation or investment decisions by corporate directors and officers. It does not directly reflect broader industry trends but is a standard part of corporate governance transparency.

Corporate Governance

Stakeholder Impact

• Shareholders: The acquisition of shares and options by a director can be seen as a positive signal, indicating alignment of interests and confidence in the company's future, potentially bolstering investor sentiment.

Next Steps

• Vesting of the 946 unvested restricted stock units upon the earlier of May 21, 2026, or the business day prior to the Company's next annual meeting of shareholders.
• Stock options becoming exercisable upon the earlier of May 21, 2026, or the business day prior to the Company's next annual meeting of shareholders.

Key Dates

Keywords

Charles River Laboratories, CRL, Insider Trading, Form 4, Stock Options, Restricted Stock Units, Director, Virginia M. Wilson, Equity Compensation